High Effectiveness of Tildrakizumab Over 52 Weeks in Patients With or Without Nail Psoriasis: Results From the Phase IV POSITIVE Austrian Subset

    Wolfgang Weger, Barbara Gruber, Gudrun Ratzinger, Leo Richter, Paul-Gunther Sator
    Studysummary Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →